An intriguing post about St John's Wort (SJW), etc.
The potencies for the uptake inhibition of NA, DA and 5-HT were 30,
7 and 1, respectively. The results indicate that the SJW Ze 117
extract interferes in three ways with the individual uptakes of the
relevant neurotransmitters that are considered to be causal in the
development of depression.
longecity.org/forum/topic/6...
Read more about...
I have not recommended that a PwP ingest SJW. The concept and findings regarding neurotransmitter reupake inhibitors may be relevant.
For instance, three items. One is a wiki snippet. Two present open access articles.
en.wikipedia.org/wiki/Dopam...
A dopamine reuptake inhibitor (DRI) is a class of drug which acts as
a reuptake inhibitor of the monoamine neurotransmitter dopamine by
blocking the action of the dopamine transporter (DAT). Reuptake
inhibition is achieved when extracellular dopamine not absorbed by
the postsynaptic neuron is blocked from re-entering the presynaptic
neuron. This results in increased extracellular concentrations of
dopamine and increase in dopaminergic neurotransmission.
Monoamine
reuptake inhibitors in Parkinson's disease.
ncbi.nlm.nih.gov/pmc/articl...
The motor manifestations of Parkinson's disease (PD) are secondary
to a dopamine deficiency in the striatum. However, the degenerative
process in PD is not limited to the dopaminergic system and also
affects serotonergic and noradrenergic neurons. Because they can
increase monoamine levels throughout the brain, monoamine reuptake
inhibitors (MAUIs) represent potential therapeutic agents in PD.
However, they are seldom used in clinical practice other than as
antidepressants and wake-promoting agents.
This review article summarises all of the available literature on
use of 50 MAUIs in PD. The compounds are divided according to their
relative potency for each of the monoamine transporters.
Despite wide discrepancy in the methodology of the studies reviewed,
the following conclusions can be drawn: (1) selective serotonin
transporter (SERT), selective noradrenaline transporter (NET), and
dual SERT/NET inhibitors are effective against PD depression; (2)
selective dopamine transporter (DAT) and dual DAT/NET inhibitors
exert an anti-Parkinsonian effect when administered as monotherapy
but do not enhance the anti-Parkinsonian actions of
L-3,4-dihydroxyphenylalanine (L-DOPA); (3) dual DAT/SERT inhibitors
might enhance the anti-Parkinsonian actions of L-DOPA without
worsening dyskinesia; (4) triple DAT/NET/SERT inhibitors might exert
an anti-Parkinsonian action as monotherapy and might enhance the
anti-Parkinsonian effects of L-DOPA, though at the expense of
worsening dyskinesia.
See also.
Natural
polyphenols: Influence on membrane transporters.
Hussain SA, Sulaiman AA, Alhaddad H, Alhadidi Q.
J Intercult Ethnopharmacol 2016 Jan
27;5(1):97-104.
ncbi.nlm.nih.gov/pmc/articl...
"Therefore, the objective of this article is to review the potential
efficacies of polyphenols in modulating the functional integrity of
uptake transporter proteins, including those terminated the effect
of neurotransmitters, and their possible influence in
neuropharmacology."
Reply (0)Report